Improved Nanoparticle Based Targeted Drug Delivery to Cancerous Cells and Tissues

Back to all technologies
Download as PDF
2017-YEO-67767
Cancer is a group of diseases involving abnormal cell growth. Currently there are more than 100 types of identified cancer that affect human beings as well as animals. In 2016, there were an estimated 1,685,210 new human cancer cases diagnosed and 595,690 cancer deaths in the United States alone (Cancer Statistics 2016 - American Cancer Society, Inc.). Nanoparticles (NPs) have been considered a promising carrier of chemotherapeutic drugs, but are limited in delivery to tumors due to the diverse nature of the disease. There currently exists the need to leverage the enhanced permeability and retention effect to deliver NPs beyond the current levels possible.

Researchers at Purdue University have developed a method for preparing polyol-modified nanoparticles for targeted delivery to cancerous cells and tissues via transcytosis across the peritumoral endothelium. This method does not depend on the leakiness of the vasculature like traditional nanoparticle formulations, but actively interacts with the vascular lining to enter tumors.

Advantages:
-Increases the amount of drugs deliver to solid tumors
-Reduces the required dose and related side effects
-Does not depend on long-term circulation and passive extravasation

Potential Applications:
-Cancer treatment
-Drug delivery

Related Publication:
Quinic Acid-Conjugated Nanoparticles Enhance Drug Delivery to Solid Tumors via Interactions with Endothelial Selectins
Small 14 (50), 1803601
DOI: https://onlinelibrary.wiley.com/doi/full/10.1002/smll.201803601
Nov 8, 2019
NATL-Patent
United States
11,154,514
Oct 26, 2021

Jan 8, 2020
NATL-Patent
China
(None)
(None)

Dec 8, 2019
NATL-Patent
Europe
(None)
(None)

May 8, 2018
PCT-Patent
WO
(None)
(None)

May 8, 2018
NATL-Patent
Canada
(None)
(None)

May 8, 2018
NATL-Patent
India
(None)
(None)

May 8, 2018
NATL-Patent
Japan
(None)
(None)

May 8, 2017
Provisional-Patent
United States
(None)
(None)
Purdue Office of Technology Commercialization
The Convergence Center
101 Foundry Drive, Suite 2500
West Lafayette, IN 47906

Phone: (765) 588-3475
Fax: (765) 463-3486
Email: otcip@prf.org